Merck & Co./$MRK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Merck & Co.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

Ticker

$MRK
Sector

Primary listing

NYSE

Employees

74,000

Merck & Co. Metrics

BasicAdvanced
$219B
13.51
$6.49
0.37
$3.24
3.70%

What the Analysts think about Merck & Co.

Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.

Bulls say / Bears say

The U.S. FDA approved a new subcutaneous formulation of Keytruda, called Keytruda Qlex, which provides one-to-two minute injections, improving patient convenience and clinic efficiency while extending market exclusivity for Merck's top-selling immunotherapy ahead of its 2028 patent expiration (Reuters).
Merck is in advanced talks to acquire London-based Verona Pharma for about $10 billion, gaining Ohtuvayre—a recently approved inhaled COPD treatment that made up 96% of Verona’s Q1 revenue—further diversifying Merck’s portfolio beyond oncology (Reuters).
Merck’s Q1 adjusted profit increased 7% to $5.61 billion, or $2.22 per share, surpassing analyst expectations despite a 2% revenue drop. The quarter included 5% growth in animal health and $280 million from the launch of its new lung disease drug Winrevair (Reuters).
Merck announced job cuts and cost-saving measures targeting $3 billion in annual savings by 2027, citing ongoing weakness in Gardasil vaccine demand in China. Q2 earnings fell 7% and Gardasil sales dropped 55% year-over-year (Reuters).
Merck slightly narrowed its full-year revenue guidance to $64.3 billion–$65.3 billion in its Q2 results, signaling reduced top-line visibility due to pressures from vaccines and tariffs (Reuters).
Merck lowered its adjusted EPS forecast for 2025 to $8.82–$8.97, down from previous guidance, after including $200 million in U.S. tariff costs and a licensing charge, reflecting margin pressure from geopolitical and partnership-related expenses (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

Merck & Co. Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Merck & Co. Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRK

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs